U29 Injection

CD30-targeted CAR-T cell therapy · Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for U29 Injection, covering 2026-03-06 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma [Phase 1]